Delivery Order SPE2DB22D2206-SPE2DB26FDT30
- Not listed
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $14,136.53 for RINVOQ ER 15 mg tablets (30-count units) on July 29, 2025, with an ultimate completion date of July 30, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order represents a single transaction under AmerisourceBergen's broader...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,931.68 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 4, 2025, with completion scheduled for August 5, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026. The pharmaceutical distributor,...
- The Defense Logistics Agency awarded a delivery order valued at $7,181.62 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) with a firm fixed price and September 23, 2025 completion date. This is a competitively awarded, non-set-aside contract for pharmaceutical supply to support federal medical procurement needs. The award was issued to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, the company's headquarters, which serves as a critical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,847.74 to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of RINVOQ ER 15 mg tablets (30-count units). This firm fixed-price delivery order, with an ultimate completion date of July 22, 2025, represents a non-set-aside competitive award to support federal pharmaceutical procurement requirements. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a $39,787.21 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) with a completion date of June 2, 2025. This competitively awarded, firm fixed-price contract was issued without a set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The contract represents a routine pharmaceutical supply delivery under AmerisourceBergen's broader relationship with the...
- The Defense Logistics Agency awarded a delivery order valued at $28.6K to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on July 14, 2025, with completion targeted for July 15, 2025. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation. The award represents a continuation of AmerisourceBergen's substantial role as a pharmaceutical supplier to federal medical procurement, leveraging the company's existing indefinite delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,111.66 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on July 22, 2025, with an ultimate completion date of July 23, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement executed through AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The place of performance is listed as Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $32,555.23 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 26, 2025, with an ultimate completion date of August 27, 2025. This competitively awarded, non-set-aside delivery order utilizes firm fixed pricing and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract vehicle with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026....
- The Defense Logistics Agency (DLA) awarded a $27,586.92 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of RINVOQ ER 30 mg tablets (30-unit bottles), with a completion date of September 25, 2025. The award was made on September 24, 2025, with no set-aside designation, indicating it was competitively awarded through open competition. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at approximately $53.1K to AmerisourceBergen Drug Corp for the supply of RINVOQ ER 15 MG tablets (30-count units) under a firm fixed-price contract. This award, issued on April 30, 2025, with an ultimate completion date of May 1, 2025, represents a competitively awarded, non-set-aside procurement. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, where the company maintains its...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB26FDT30Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $45,662.38 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets in quantities of 30s, with an ultimate completion date of October 23, 2025. This firm fixed price delivery order represents a non-competitive, non-set-aside award to the major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania. The award leverages AmerisourceBergen's position as a critical vendor within the federal medical supply chain, particularly for military and veteran healthcare systems. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The prime IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a wide range of medications and medical supplies to support military healthcare programs worldwide. AmerisourceBergen's contract portfolio demonstrates consistent capability to meet federal procurement requirements through open competition, with delivery orders covering diverse pharmaceutical products across multiple therapeutic domains including specialty medications, brand-name and generic drugs, and vaccines to support Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $45.7k | 10/22/25 |